Editorial Office, Translational Lung Cancer Research (TLCR). Email: editor@tlcr.org
On September 7, 2026, we received the good news from DOAJ (the Directory of Open Access Journals) that Translational Lung Cancer Research (TLCR) has been accepted for inclusion in DOAJ. The information of TLCR on DOAJ is available at: https://doaj.org/toc/2226-4477.
DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community. It is committed to ensuring quality content is openly available online for everyone. DOAJ works to build an equitable and diverse scholarly ecosystem where trusted research can be accessed globally without barriers.
Inclusion in the DOAJ marks an essential milestone for TLCR and confirms its presence in the growing infrastructure of free-to-read content in academic publishing.
Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Online ISSN 2226-4477) is an international, peer-reviewed, open access journal, which was founded in March 2012. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. TLCR is dedicated to focus on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”. The aim of TLCR is to provide a forum for the dissemination of original research and review articles in all areas related to lung cancer, as well as a timely platform for the exchange of key opinions between leading experts, and so to provide readers with a novel, well-organized, informative, enlightening and educational journal. TLCR is indexed by Web of Science [Science Citation Index Expanded (SCIE)], PubMed/PubMed Central, Scopus, the Chemical Abstracts Service (CAS) Databases, and DOAJ.